FDA Classifies New Tinnitus Stimulation Device
Published Date: 6/10/2026
Rule
Summary
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Device reclassified to Class II, speeding access
The FDA classified the combined acoustic and electrical external stimulation device for tinnitus as Class II (special controls), effective June 10, 2026, and applicable retroactively to March 6, 2023. FDA says this Class II classification reduces regulatory burdens compared with automatic Class III assignment and will enhance patients' access to this device.
Creates a predicate pathway for future devices
FDA's De Novo classification means this device type can serve as a predicate for future substantially equivalent devices, allowing other sponsors to use the less burdensome 510(k) premarket notification process instead of De Novo or premarket approval. The order explains that after classification into class I or II via De Novo, future device sponsors can rely on this device as a predicate.
Mandatory safety tests and prescriber-only labeling
The Class II order imposes special controls requiring clinical performance testing, non-clinical verification of electrical and acoustic parameters, electromagnetic compatibility and battery safety testing, software verification/validation and hazard analysis, biocompatibility of patient-contacting components, and human factors testing. Labeling must state that the device is intended to be prescribed by a healthcare professional with expertise in evaluation and management of tinnitus and must include device specifications (e.g., electrical output waveform, stimulation peak voltage and current, pulse duration, frequency, maximum current density, maximum phase charge, and power source).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
2026-11429 — Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
2026-11302 — Medical Devices; Orthopedic Devices; Classification of the Absorbable Metallic Bone Fixation Fastener
The FDA is officially classifying absorbable metallic bone fixation fasteners as Class II devices with special safety rules, making them easier to get to patients while keeping them safe and effective. This change helps doctors and patients by reducing red tape and encouraging new, helpful bone-fixing tech. The new rules took effect on June 5, 2026, but have been in place since March 29, 2023, so manufacturers should already be on board.
2026-11303 — Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
2026-11306 — Medical Devices; Orthopedic Devices; Classification of the Shoulder Joint Humeral (Hemi-Shoulder) Ceramic Head/Metallic Stem Cemented or Uncemented Prosthesis
The FDA is officially putting the shoulder joint humeral ceramic head/metallic stem prosthesis into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps patients get safer, innovative shoulder implants faster and makes life easier for makers by lowering regulatory costs. The new classification is effective June 5, 2026, but has been in effect since December 16, 2022.
2026-11308 — Medical Devices; Orthopedic Devices; Classification of the Resorbable Calcium Salt Bone Void Filler Containing a Single Approved Aminoglycoside Antibacterial
The FDA is officially putting a special bone filler that slowly dissolves and fights bacteria into a safer, easier-to-manage category called Class II. This change helps make sure the product is safe and effective while speeding up patient access to this cool new tech. It’s been in effect since May 2022, so companies and patients can expect smoother approvals and fewer hoops to jump through.
Previous / Next Documents
Previous: 2026-11585 — Penalty Inflation Adjustments for Civil Monetary Penalties
Starting June 10, 2026, the Social Security Administration is updating its civil penalty amounts to keep up with inflation. This means fines for breaking certain rules will be a bit higher to match today’s prices. If you deal with SSA rules, watch out—penalties are now adjusted every year to stay fair and current!
Next: 2026-11592 — Publication of Cyber-Related Sanctions Regulations Web General License 2
The Treasury’s Office of Foreign Assets Control (OFAC) officially published General License 2, which lets certain water treatment and distribution transactions with Anco Water Supply Co. Ltd. happen, even though sanctions usually block them. This change helps companies involved in drinking water services keep things flowing smoothly without breaking the rules. The license took effect on April 23, 2026, so affected businesses should act now to stay compliant and avoid penalties.